title: [Preoperative serum α-1-fucosidase as an early-recurrent indicator for hepatocellular carcinoma following curative resection].
abstract: OBJECTIVE
  To investigate the early-recurrence prediction value of preoperative alpha-1-fucosidase (AFU) for hepatocellular carcinoma (HCC) patients undergoing curative resection.
  
  
  METHODS
  A retrospective training set data from January to July, 2012 including 116 patients and a prospective validation set from August 2012 to December 2012 including 68 patients were used to validate the predictive value of preoperative AFU. Difference of recurrence rates between low and high AFU populations in all HCC or early-HCC subgroups were compared via Kaplan-Meier curves and Log-rank tests. Univariate and multivariate analyses were used to identify the recurrent prediction value of preoperative serum AFU.
  
  
  RESULTS
  Based on retrospective training data, AFU = 25.00 U/L was set as the optimal cutoff point to stratify HCC patients into high (>25.00 U/L) and low ( ≤ 25.00 U/L) groups. Patients with high preoperative AFU showed significant low tumor-free survival not only in whole patients group (mean 12.50 months vs.not reached; P < 0.01) but also in early-HCC (mean 10.25 months vs.not reached, P < 0.01) and AFP negative subgroups (mean 13.20 months vs not reached, P < 0.01). Univariate and multivariate analyses revealed the AFU was an independent predictor for tumor recurrence (OR = 1.72, 95%CI:1.00-2.96, P = 0.04). The prospective validation data confirmed the predictive value of preoperative AFU in HCC (OR = 2.22, 95%CI:0.67-7.37, P = 0.04). Furthermore, patients with high preoperative AFU were prone to have bigger tumor and form vascular invasion.
  
  
  CONCLUSIONS
  Preoperative AFU is a powerful prognostic indicator for HCC and 25.00 U/L might be an optimal recurrence prediction cutoff value for patients in Zhongshan hospital.
authors.affiliation: Department of Laboratory Medicine,Zhongshan Hospital, Fudan University, Shanghai 200032, China.
authors.forename: Yan
authors.initials: Y
authors.lastname: Zhou
authors.affiliation: Department of Laboratory Medicine,Zhongshan Hospital, Fudan University, Shanghai 200032, China.
authors.forename: Xiaolu
authors.initials: X
authors.lastname: Ma
authors.affiliation: Department of Laboratory Medicine,Zhongshan Hospital, Fudan University, Shanghai 200032, China.
authors.forename: Jiong
authors.initials: J
authors.lastname: Wu
authors.affiliation: Department of Laboratory Medicine,Zhongshan Hospital, Fudan University, Shanghai 200032, China.
authors.forename: Chunyan
authors.initials: C
authors.lastname: Zhang
authors.affiliation: Department of Laboratory Medicine,Zhongshan Hospital, Fudan University, Shanghai 200032, China.
authors.forename: Beili
authors.initials: B
authors.lastname: Wang
authors.affiliation: Department of Laboratory Medicine,Zhongshan Hospital, Fudan University, Shanghai 200032, China.
authors.forename: Binbin
authors.initials: B
authors.lastname: Song
authors.affiliation: Department of Laboratory Medicine,Zhongshan Hospital, Fudan University, Shanghai 200032, China.
authors.forename: Wei
authors.initials: W
authors.lastname: Guo
authors.affiliation: Department of Laboratory Medicine,Zhongshan Hospital, Fudan University, Shanghai 200032, China. Email:pan.baishen@zs-hospital.sh.cn.
authors.forename: Baishen
authors.initials: B
authors.lastname: Pan
mesh_terms: D006528:Carcinoma, Hepatocellular; D006801:Humans; D008113:Liver Neoplasms; D015999:Multivariate Analysis; D011379:Prognosis; D011446:Prospective Studies; D012008:Recurrence; D012189:Retrospective Studies; D005644:alpha-L-Fucosidase
chemical_list: D005644:alpha-L-Fucosidase